AR087276A1 - Composiciones y metodos para tratar policitemia vera y trombocitemia esencial - Google Patents

Composiciones y metodos para tratar policitemia vera y trombocitemia esencial

Info

Publication number
AR087276A1
AR087276A1 ARP120102656A ARP120102656A AR087276A1 AR 087276 A1 AR087276 A1 AR 087276A1 AR P120102656 A ARP120102656 A AR P120102656A AR P120102656 A ARP120102656 A AR P120102656A AR 087276 A1 AR087276 A1 AR 087276A1
Authority
AR
Argentina
Prior art keywords
methods
compositions
vera
essential
thrombocitemia
Prior art date
Application number
ARP120102656A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR087276A1 publication Critical patent/AR087276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)

Abstract

Composiciones y métodos para tratar policitemia vera (PV) y/o trombocitemia esencial (ET) en un sujeto. Los métodos comprenden administrar al sujeto una cantidad eficaz de compuesto que es N-terc-butil-3-[(5-metil-2-{[4-(2-pirrolidin-1-iletoxi)fenil]amino}pirimidin-4-il)amino]bencenosulfonamida o una sal farmacéuticamente aceptable o un hidrato de éste.
ARP120102656A 2011-07-21 2012-07-20 Composiciones y metodos para tratar policitemia vera y trombocitemia esencial AR087276A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510409P 2011-07-21 2011-07-21
US201161510406P 2011-07-21 2011-07-21
FR1251749 2012-02-27
FR1251748 2012-02-27

Publications (1)

Publication Number Publication Date
AR087276A1 true AR087276A1 (es) 2014-03-12

Family

ID=47558514

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102656A AR087276A1 (es) 2011-07-21 2012-07-20 Composiciones y metodos para tratar policitemia vera y trombocitemia esencial

Country Status (3)

Country Link
AR (1) AR087276A1 (es)
TW (1) TW201316989A (es)
WO (1) WO2013013195A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
FR3092581A1 (fr) * 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025685A1 (en) * 2009-08-24 2011-03-03 Merck Sharp & Dohme Corp. Jak inhibition blocks rna interference associated toxicities

Also Published As

Publication number Publication date
TW201316989A (zh) 2013-05-01
WO2013013195A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
BR112014016805A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CL2016000241A1 (es) Formulación de inhibidores de la syk.
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
GT201300266A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
BR112013025386A2 (pt) combinação de um composto, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de uma doença ou afecção modulada por mutação braf v600e e altos níveis de pakt em um mamífero e uso
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
IN2014MN01755A (es)
IN2014DN10386A (es)
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
ECSP13012764A (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR
ECSP13013011A (es) Triazolopiridinas
MX2014003025A (es) Compuestos de triazolopiridina como inhibidores de fosfodiesterasa 10a.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
EA201390755A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
AR087276A1 (es) Composiciones y metodos para tratar policitemia vera y trombocitemia esencial
MX2013014398A (es) Derivados de sulfonamida heterociclicos.
CL2013003556A1 (es) Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
CL2012002358A1 (es) Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal